Thanks BR,
Partnering is just a development strategy, and completely agree, it can be a balls up for a number of reasons, wont elaborate here.
Array is in oncology so a tougher market IMO, expect lower upfronts and more milestone related payments in oncology than for the Cholesterol opportunities. I could be wrong, need to go have a look at partnering deals in that space to confirm...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.015(6.38%) |
Mkt cap ! $52.72M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 25.0¢ | 23.5¢ | $133.6K | 560.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 31961 | 23.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 26751 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |